Abvc Biopharma (ABVC) Gains from Investment Securities (2018 - 2019)
Abvc Biopharma's (ABVC) quarterly Gains from Investment Securities came in at $66205.0 in Q1 2019, up 71.66% YoY from $38567.0 in Q1 2018, and down 97.07% on a QoQ basis from $2.3 million in Q4 2018.
Abvc Biopharma (ABVC) Gains from Investment Securities (2018 - 2019) Analysis & Trends
Abvc Biopharma (ABVC) has 2 years of Gains from Investment Securities data on file, last reported at $66205.0 in Q1 2019.
- Quarterly Gains from Investment Securities rose 71.66% year-over-year to $66205.0 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $2.6 million (changed N/A YoY) and the FY2018 annual result came in at $2.5 million, changed N/A from the prior year.
- Gains from Investment Securities declined to $66205.0 in Q1 2019, from $2.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.3 million in Q4 2018 to a low of $38567.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 66,205.00 |
| Mar 31, 2019 | 66,205.00 |
| Dec 31, 2018 | 2.26 Mn |
| Dec 31, 2018 | 2.26 Mn |
| Sep 30, 2018 | 201,590.00 |
| Sep 30, 2018 | 201,590.00 |
| Jun 30, 2018 | 47,356.00 |
| Jun 30, 2018 | 47,356.00 |
| Mar 31, 2018 | 38,567.00 |
| Mar 31, 2018 | 38,567.00 |